3652 results for «238»
3652 results
Imaging evaluation in structural heart interventions
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive evaluation of imaging techniques applied in structural heart interventions. It covers innovative studies including the impact of Dapagliflozin on multivalvular disease post-TAVI, advanced fusion methods combining CT and echocardiography to assess aortic stenosis severity, and the clinical relevance of the fibrocalcific...
New platforms for coronary lesions treatment
21 May 2026 – From EuroPCR 2026
Delve into the latest developments in coronary lesion treatment platforms through this session, highlighting real-world performance data of novel drug-eluting stents like Eternia and Evermine 50. It also presents preclinical insights on biomimetic CD31-coated stents, long-term outcomes of the Fantom BRS platform, and innovative randomized trials...
Left main complications - Part 2
21 May 2026 – From EuroPCR 2026
This session covers intricate complications involving the left main coronary artery (LMCA), highlighting cases of catheter-induced dissections, challenges in chronic total occlusion (CTO) PCI, and rare scenarios such as stent entrapment and complex re-interventions. Emphasis is placed on the critical utility of intravascular ultrasound (IVUS) and...
Percutaneous management of mitral and aortic valve disease
21 May 2026 – From EuroPCR 2026
Delve into the percutaneous management of mitral and aortic valve disease through detailed procedural demonstrations. This session covers valve-in-valve procedures, navigation of potential complications in valve-in-valve TAVI, and mitral valve edge-to-edge repair techniques, supported by real-world case discussions and key learnings.
Refining the gold standard: what is new in DES
21 May 2026 – From EuroPCR 2026
This session explores recent advancements in drug-eluting stent (DES) technology, featuring global real-world evidence on short dual antiplatelet therapy (DAPT) with polymer-free DES, angiographic outcomes from pooled TARGET trials, and real-world registry data on various DES platforms. It also presents post-marketing surveillance results and systematic reviews...
Complex multivessel disease: from calcium to physiology - Case-based decisions
21 May 2026 – From EuroPCR 2026
Focus on complex multivessel coronary artery disease management with an emphasis on severely calcified lesions and the integration of intracoronary imaging and physiology. This session prepares clinicians to anticipate and manage complications during PCI, enhancing competence in treating challenging coronary anatomies through case-based decision-making.
Pharmacology without borders, from coronary artherostenosis to radial artery
21 May 2026 – From EuroPCR 2026
This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...
Innovations in TAVI: TAVI 2.0
21 May 2026 – From EuroPCR 2026
This session presents cutting-edge advancements in transcatheter aortic valve implantation (TAVI), highlighting the TAVI 2.0 era. It encompasses innovative techniques such as percutaneous and non-fluoroscopic TAVR guided by transthoracic echocardiography (TTE), novel alternative access via the left subscapular approach, and patient-tailored commissural alignment assessed through CT...
Impact of intravascular imaging guidance on percutaneous coronary intervention of severely calcified lesions: The ECLIPSE trial
29 Mar 2025
Aaysha Cader provides her take on the ECLIPSE trial presented by Gregg W. Stone at ACC.25 in Chicago.
Author
PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction
03 Apr 2022
Nicola Ryan provides a PICOT analysis of PACMAN AMI: a double-blind, placebo-controlled, randomized trial presented at ACC 2022 and simultaneously published in JAMA.
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Comparison of a precision care strategy with usual testing to guide management of stable patients with suspected CAD: the PRECISE randomized trial
09 Nov 2022
Alex Sticchi provides his take on PRECISE, which was presented during AHA 2022 in Chicago.
Author
